
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7883013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diabetes mellitus and tuberculosis facts and controversies. Journal of Diabetes and Metabolic Disorders, 2013, 12, 58.	1.9	90
2	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. International Journal of Infectious Diseases, 2009, 13, e236-e240.	3.3	69
3	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. International Immunopharmacology, 2020, 85, 106688.	3.8	67
4	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. European Journal of Pharmacology, 2021, 897, 173947.	3.5	66
5	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. International Immunopharmacology, 2021, 90, 107205.	3.8	64
6	Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. Journal of Clinical Immunology, 2020, 40, 974-976.	3.8	59
7	Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 592727.	4.8	53
8	Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran. American Journal of Therapeutics, 2011, 18, e29-e34.	0.9	51
9	Lethal Tuberculosis in a Previously Healthy Adult with IL-12 Receptor Deficiency. Journal of Clinical Immunology, 2011, 31, 537-539.	3.8	49
10	The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infectious Diseases, 2008, 8, 109.	2.9	43
11	Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. American Journal of Therapeutics, 2010, 17, 17-22.	0.9	43
12	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology, 2020, 88, 106869.	3.8	40
13	Pulmonary disease caused by Mycobacterium simiae in Iran's national referral center for tuberculosis. Journal of Infection in Developing Countries, 2012, 6, 23-28.	1.2	39
14	Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. New England Journal of Medicine, 2020, 382, 437-445.	27.0	38
15	Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. International Archives of Allergy and Immunology, 2021, 182, 254-262.	2.1	36
16	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. American Journal of the Medical Sciences, 2009, 337, 182-184.	1.1	35
17	Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal of STD and AIDS, 2012, 23, e1-e4.	1.1	35
18	Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study. Journal of Diabetes and Metabolic Disorders, 2014, 13, 123.	1.9	33

#	Article	IF	CITATIONS
19	Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology, 2021, 27, 486-492.	2.1	33
20	Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy [Short communication]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 547-550.	1.2	30
21	Diagnosis of Latent Tuberculosis Infection Among Immunodeficient Individuals: Review of Concordance Between Interferon-γ Release Assays and the Tuberculin Skin Test. British Journal of Biomedical Science, 2014, 71, 115-124.	1.3	30
22	Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients. Pathology Research and Practice, 2020, 216, 153228.	2.3	30
23	A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. Iranian Journal of Pharmaceutical Research, 2020, 19, 31-36.	0.5	30
24	Comparison of Serum and Bronchoalveolar Lavage Galactomannan in Diagnosing Invasive Aspergillosis in Solid-Organ Transplant Recipients. Experimental and Clinical Transplantation, 2012, 10, 278-281.	0.5	29
25	Tuberculosis-Associated Secondary Pneumothorax: A Retrospective Study of 53 Patients. Respiratory Care, 2011, 56, 298-302.	1.6	28
26	Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. Annals of Thoracic Medicine, 2011, 6, 91.	1.8	25
27	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microbial Drug Resistance, 2010, 16, 81-86.	2.0	22
28	Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical and Genetic Features of 32 Iranian Patients. Journal of Clinical Immunology, 2020, 40, 872-882.	3.8	22
29	Effect of bromhexine in hospitalized patients with COVID-19. Journal of Investigative Medicine, 2023, 71, 691-699.	1.6	22
30	Impact of chronic renal failure on anti-tuberculosis treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 352-356.	1.2	21
31	Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 2016, 15, 247-52.	0.5	21
32	The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality. Scientific Reports, 2021, 11, 17594.	3.3	20
33	Myocarditis following rAd26 and rAd5 vectorâ€based COVIDâ€19 vaccine: case report. ESC Heart Failure, 2022, 9, 1483-1486.	3.1	19
34	Novel T-Cell Assays for the Discrimination of Active and Latent Tuberculosis Infection: The Diagnostic Value of PPE Family. Molecular Diagnosis and Therapy, 2015, 19, 309-316.	3.8	18
35	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. Immunological Investigations, 2021, 50, 884-890.	2.0	18
36	Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases. American Journal of Therapeutics, 2011, 18, 343-349.	0.9	17

#	Article	IF	CITATIONS
37	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. Journal of Global Antimicrobial Resistance, 2016, 4, 1-4.	2.2	17
38	Immune cell profiling and antibody responses in patients with COVID-19. BMC Infectious Diseases, 2021, 21, 646.	2.9	17
39	Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis. Scandinavian Journal of Infectious Diseases, 2012, 44, 369-373.	1.5	16
40	Discriminating between latent and active tuberculosis: The role of interleukin-2 as biomarker. Journal of Infection, 2015, 70, 429-431.	3.3	16
41	Serum cytokine levels of COVID-19 patients after 7Âdays of treatment with Favipiravir or Kaletra. International Immunopharmacology, 2021, 93, 107407.	3.8	16
42	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology, 2021, 92, 107329.	3.8	15
43	Impact of HIV infection on tuberculous pleural effusion. International Journal of STD and AIDS, 2016, 27, 363-369.	1.1	14
44	Paecilomyces formosus Infection in an Adult Patient with Undiagnosed Chronic Granulomatous Disease. Journal of Clinical Immunology, 2017, 37, 342-346.	3.8	13
45	Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 45-49.	0.2	13
46	Drug abuse profile – patient delay, diagnosis delay and drug resistance pattern – among addict patients with tuberculosis. International Journal of STD and AIDS, 2009, 20, 320-323.	1.1	12
47	Diagnostic accuracy of interferon (IFN)-γ inducible protein 10 (IP-10) as a biomarker for the discrimination of active and latent tuberculosis. Molecular Biology Reports, 2019, 46, 6263-6269.	2.3	12
48	Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion. Scientific Reports, 2021, 11, 660.	3.3	12
49	The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review. Current Therapeutic Research, 2022, 96, 100658.	1.2	12
50	Radiologic manifestations of pulmonary tuberculosis in patients of intensive care units. International Journal of Mycobacteriology, 2015, 4, 233-238.	0.6	11
51	Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iranian Journal of Pharmaceutical Research, 2020, 19, 1-2.	0.5	11
52	Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: A single-center study. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, 26, 6.	0.3	11
53	Improving T-cell assays for diagnosis of latent TB infection: Confirmation of the potential role of testing Interleukin-2 release in Iranian patients. Allergologia Et Immunopathologia, 2016, 44, 314-321.	1.7	10
54	Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-6.	1.9	10

#	Article	IF	CITATIONS
55	Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 138-142.	0.6	10
56	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. Tanaffos, 2020, 19, 91-99.	0.5	10
57	Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form Iranian Journal of Pharmaceutical Research, 2021, 20, 1-8.	0.5	10
58	Pulmonary Aspergillosis in Solid Organ Transplant Patients: A Report From Iran. Transplantation Proceedings, 2008, 40, 3663-3667.	0.6	9
59	First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran. International Journal of STD and AIDS, 2009, 20, 566-570.	1.1	9
60	Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. Brazilian Journal of Infectious Diseases, 2014, 18, 487-490.	0.6	9
61	Performance of QuantiFERON TB Gold test in detecting latent tuberculosis infection in brain-dead organ donors in Iran: A brief report. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2014, 25, 1240.	0.3	9
62	Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. Brazilian Journal of Infectious Diseases, 2010, 14, 639-640.	0.6	8
63	Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. Pediatric Rheumatology, 2021, 19, 121.	2.1	8
64	Improving the Practice of Nutrition Therapy in the NRITLD Critically Ill Patients: An International Quality Improvement Project. Tanaffos, 2011, 10, 31-7.	0.5	8
65	Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran. Tanaffos, 2015, 14, 262-7.	0.5	8
66	Eight Years of Lung Transplantation: Experience of the National Research Institute of Tuberculosis and Lung Diseases. Transplantation Proceedings, 2009, 41, 2887-2889.	0.6	7
67	Treatment outcome and mortality: Their predictors among HIV/TB co-infected patients from Iran. International Journal of Mycobacteriology, 2012, 1, 82-86.	0.6	7
68	Characterization of Clostridioides difficile isolates recovered from hospitalized patients and the hospitals environment and air: A multicenter study. Anaerobe, 2019, 59, 154-158.	2.1	7
69	Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. Human Antibodies, 2021, 29, 109-113.	1.5	7
70	Diagnostic Accuracy of Monocyte Chemotactic Protein (MCP)-2 as Biomarker in Response to PE35/PPE68 Proteins: A Promising Diagnostic Method for the Discrimination of Active and Latent Tuberculosis. Protein and Peptide Letters, 2019, 26, 281-286.	0.9	7
71	Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series. Annals of Clinical Microbiology and Antimicrobials, 2022, 21, 8.	3.8	7
72	The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. Journal of Research in Medical Sciences, 2020, 25, 24.	0.9	7

#	Article	IF	CITATIONS
73	Screening for diabetes mellitus in tuberculosis patients in a referral center in Iran. Infectious Diseases, 2015, 47, 472-476.	2.8	6
74	Pulmonary Actinomycosis in a Patient with AIDS/HCV. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OD15-OD17.	0.8	6
75	Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, Iran. Tanaffos, 2011, 10, 8-11.	0.5	6
76	Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19. Tanaffos, 2020, 19, 85-88.	0.5	6
77	miR-1224 Expression Is Increased in Human Macrophages after Infection with Bacillus Calmette-Guérin (BCG). Iranian Journal of Allergy, Asthma and Immunology, 2018, 17, 250-257.	0.4	6
78	Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient. Avicenna Journal of Medicine, 2014, 4, 17.	0.8	5
79	An adult autosomal recessive chronic granulomatous disease patient with pulmonary Aspergillus terreus infection. BMC Infectious Diseases, 2018, 18, 552.	2.9	5
80	Disseminated Kaposi′s sarcoma with the involvement of penis in the setting of Hiv infection. Indian Journal of Dermatology, 2015, 60, 104.	0.3	5
81	Acute Epstein - Barr virus hepatitis without mononucleosis syndrome: a case report. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, 147-149.	0.6	5
82	Microbial Pattern of BronchoAlveolar Lavage in Brain Dead Donors. Transplantation Proceedings, 2011, 43, 422-423.	0.6	4
83	HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12-year study. International Journal of Mycobacteriology, 2016, 5, S16-S17.	0.6	4
84	Pathogenicity locus determinants and toxinotyping of Clostridioides difficile isolates recovered from Iranian patients. New Microbes and New Infections, 2018, 25, 52-57.	1.6	4
85	Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillus nidulans complex and Aspergillus terreus complex isolated from clinical specimens. Journal De Mycologie Medicale, 2020, 30, 101004.	1.5	4
86	Implementing tuberculosis close-contact investigation in a Tertiary Hospital in Iran. International Journal of Preventive Medicine, 2018, 9, 48.	0.4	4
87	Incidence of Thromboembolism in Hospitalized Patients With Tuberculosis and Associated Risk Factors. Archives of Clinical Infectious Diseases, 2012, 7, .	0.2	4
88	Tuberculosis in Solid Organ Transplantation. Tanaffos, 2016, 15, 124-127.	0.5	4
89	A Novel Coronavirus Disease (COVID-19): a Review of Host Cell Signaling Pathways. Tanaffos, 2020, 19, 108-111.	0.5	4
90	Yield of mycobacteriological study in diagnosis of pleural tuberculosis among Human immune deficiency virus-infected patients. International Journal of Mycobacteriology, 2016, 5, S112-S113.	0.6	3

#	Article	IF	CITATIONS
91	Investigation of urine lipoarabinomannan in human immunodeficiency virus patients with or without coinfection with Tuberculosis in Iran. International Journal of Mycobacteriology, 2016, 5, S186-S187.	0.6	3
92	Delay in the Diagnosis of APECED: A Case Report and Review of Literature from Iran. Immunological Investigations, 2020, 49, 299-306.	2.0	3
93	Differential Gene Expression of ASUN, NEMF, PTPRC and DHX29: Candidate Biomarkers for the Diagnosis of Active and Latent Tuberculosis. Infectious Disorders - Drug Targets, 2021, 21, 268-273.	0.8	3
94	Cutaneous Alternariosis With Trichosporon Infection in a Heart Transplant Recipient: A Case Report. Experimental and Clinical Transplantation, 2013, 11, 464-466.	0.5	3
95	The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. Journal of Research in Medical Sciences, 2020, 25, 24.	0.9	3
96	Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. Tanaffos, 2020, 19, 122-128.	0.5	3
97	T Helper Cell Subsets in the Pleural Fluid of Tuberculous Patients Differentiate Patients With Non-Tuberculous Pleural Effusions. Frontiers in Immunology, 2021, 12, 780453.	4.8	3
98	Pulmonary manifestations in a cohort of patients with inborn errors of immunity: an 8-year follow-up study. Allergologia Et Immunopathologia, 2022, 50, 80-84.	1.7	3
99	Transmission electron microscopy study of suspected primary ciliary dyskinesia patients. Scientific Reports, 2022, 12, 2375.	3.3	3
100	National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19. Iranian Journal of Pharmaceutical Research, 2022, 21, .	0.5	3
101	A Case of Chronic Granulomatous Disease with a Necrotic Mass in the Bronchus: A Case Report and a Review of Literature. Case Reports in Pulmonology, 2012, 2012, 1-4.	0.3	2
102	Recurrent Drug-Induced Hepatitis in Tuberculosis—Comparison of Two Drug Regimens. American Journal of Therapeutics, 2017, 24, e144-e149.	0.9	2
103	Diagnosing active and latent tuberculosis among Iranian HIVâ€infected patients. Clinical Respiratory Journal, 2018, 12, 62-67.	1.6	2
104	Disseminated Mycobacterium simiae Infection in a Patient with Complete IL-12p40 Deficiency. Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 376-381.	0.4	2
105	Clinical and radiological deterioration due to Mycobacterium szulgai in an asthmatic patient. Journal of Infection in Developing Countries, 2012, 6, 89-91.	1.2	2
106	H1N1 Influenza Patient Saved by Extracorporeal Membrane Oxygenation: First Report from Iran. The Journal of Tehran Heart Center, 2016, 11, 153-156.	0.3	2
107	Caspofungin as Salvage Therapy for Pneumocystis Pneumonia in a Heart Transplant Recipient. Tanaffos, 2018, 17, 203-206.	0.5	2
108	Value of third sputum smear for detection of pulmonary tuberculosis in HIV infected patients. Gastroenterology Insights, 2012, 4, 35.	1.2	1

#	Article	IF	CITATIONS
109	Multidrug-resistant tubercular appendicitis: Report of a case. International Journal of Mycobacteriology, 2013, 2, 227-229.	0.6	1
110	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. International Journal of Mycobacteriology, 2015, 4, 128.	0.6	1
111	Usefulness of pulmonary artery diameter in diagnosing pulmonary hypertension in patients admitted to tuberculosis intensive care unit. International Journal of Mycobacteriology, 2016, 5, S56.	0.6	1
112	Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. Journal of Global Antimicrobial Resistance, 2017, 11, 116-119.	2.2	1
113	Multimorbidity among persons living with human immunodeficiency virus in a moroccan referral hospital. International Journal of Mycobacteriology, 2022, 11, 16.	0.6	1
114	Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. Brazilian Journal of Infectious Diseases, 2010, 14, 639-640.	0.6	1
115	Evaluation of treatment response in active tuberculosis using QuantiFERON-TB Gold Plus. European Cytokine Network, 2020, 31, 129-133.	2.0	1
116	Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. Tanaffos, 2020, 19, 291-299.	0.5	1
117	Trisomy 21 as a Risk Factor for Severe Illness in COVID-19: Report of two Cases. Tanaffos, 2020, 19, 413-417.	0.5	1
118	The Effect of acetyl-L-carnitine, Alpha-lipoic Acid, and Coenzyme Q10 Combination in Preventing Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized, Double-blind, Placebo-controlled Clinical Trial Iranian Journal of Pharmaceutical Research, 2021, 20, 431-440.	0.5	1
119	A Young Woman with Diffuse Skin Lesions. Clinical Infectious Diseases, 2010, 51, 195-196.	5.8	0
120	807. Critical Care Medicine, 2013, 41, A201.	0.9	0
121	Detection of latent and active tuberculosis among HIV-positive patients at the North of Tehran. International Journal of Mycobacteriology, 2015, 4, 64.	0.6	0
122	Outcome of drug-resistant tuberculosis treatment among HIV-positive patients at the tertiary center in Tehran. International Journal of Mycobacteriology, 2015, 4, 115.	0.6	0
123	Risk factors for mortality among tuberculosis patients co-infected with HIV. Infectious Diseases, 2018, 50, 399-402.	2.8	0
124	Tuberculosis and COVID-19 co-infection: A case series from Iran. International Journal of Mycobacteriology, 2021, 9, 3.	0.6	0
125	Value of serologic assay in diagnosis of COVID-19 among patients with negative molecular assay. International Journal of Mycobacteriology, 2021, 9, 62.	0.6	0
126	Not all that is miliary is tuberculosis: Metastatic medullary thyroid carcinoma mimicking miliary tuberculosis. Clinical Case Reports (discontinued), 2021, 9, e04231.	0.5	0

#	Article	IF	CITATIONS
127	Impact of clinical pharmacistâ€led antibiotic stewardship program on clinical outcomes in a tertiary referral hospital. Journal of Pharmacy Practice and Research, 0, , .	0.8	Ο
128	Botryotrichum infection in an adult patient with undiagnosed chronic granulomatous disease. , 2016, , .		0
129	A Potentially Fatal Error in Diagnosis of a Pulmonary Hydatid Cyst. Archives of Clinical Infectious Diseases, 2017, 13, .	0.2	0
130	Antifungal Resistant Gastrointestinal Basidiobolomycosis Without Eosinophilia: A Case Report. Archives of Clinical Infectious Diseases, 2017, 12, .	0.2	0
131	Incidence of Phlebitis Associated With Peripheral Venous Catheter of Patients With COVID-19. Hospital Practices and Research, 2020, 5, 79-80.	0.2	0
132	Evaluation of Th9 and Th22 cells within pleural effusions of tuberculosis and non-tuberculosis patients. , 2020, , .		0
133	Clinical outcomes and complications ofÂfiberoptic bronchoscopy in HIV-infected patients. HIV and AIDS Review, 2020, 19, 172-179.	0.2	0
134	Management of MDR-TB: Review of Iran's Experience. Tanaffos, 2013, 12, 6-15.	0.5	0
135	A 60 year-old man with AIDS and pneumonia. Tanaffos, 2013, 12, 61-2.	0.5	Ο
136	Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital. Tanaffos, 2018, 17, 183-187.	0.5	0
137	Etiology of Respiratory Complications among Iranian HIV Infected Patients. Tanaffos, 2019, 18, 96-103.	0.5	Ο
138	Enterovirus-Human Rhinovirus as a Leading Cause of ARDS in a Liver Transplant Recipient. Tanaffos, 2019, 18, 169-172.	0.5	0
139	Differential genes expression analysis of invasive aspergillosis: a bioinformatics study based on mRNA/microRNA. Molecular Biology Research Communications, 2020, 9, 173-180.	0.3	Ο
140	Evaluation of inflammatory mediators of pleural effusion in tuberculosis and non-tuberculosis patients. , 2020, , .		0
141	Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 394-401.	0.4	Ο
142	Bronchial Angioembolization for Management of Hemoptysis Due to Pulmonary Tuberculosis Tanaffos, 2021, 20, 134-139.	0.5	0
143	Descriptive Analysis of COVID-19 among Health Care Workers in a Tertiary Center in Iran Tanaffos, 2021, 20, 246-252.	0.5	0
144	NRITLD Protocol for the Management of Outpatient Cases of COVID-19 Tanaffos, 2021, 20, 192-196.	0.5	0